Multidisciplinary consensus on the use of hydroxychloroquine in patients with systemic lupus erythematosus.
Íñigo Rúa-FigueroaTarek Carlos Salman-MonteJosé María Pego ReigosaMaría Galindo IzquierdoElvira Díez ÁlvarezAntonio Fernández-NebroJosé Andrés Román IvorraInmaculada Calvo PenadesJoseba Artaraz BeobideJaime Calvo AlénPublished in: Reumatologia clinica (2024)
The available evidence supports HCQ's effectiveness and safety for SLE. Individualized assessment of the initial HCQ dose is important, especially in situations requiring dose reduction or discontinuation. This risk-benefit assessment, specifically focusing on the balance between retinal toxicity and the risk of SLE relapse, should guide decisions regarding medication withdrawal, considering disease activity, risk factors, and HCQ potential benefits. Close monitoring is essential for optimal disease management and minimize potential risks, such as QT prolongation or retinal toxicity.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- risk factors
- optical coherence tomography
- human health
- diabetic retinopathy
- juvenile idiopathic arthritis
- oxidative stress
- drug induced
- optic nerve
- healthcare
- risk assessment
- emergency department
- clinical practice
- climate change
- adverse drug
- oxide nanoparticles
- electronic health record